Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 213 Lung Neoplasms 79 Triple Negative Breast Neoplasms 67 Breast Neoplasms 67 Ovarian Neoplasms 56 Squamous Cell Carcinoma of Head and Neck 49 Small Cell Lung Carcinoma 47 Fallopian Tube Neoplasms 37 Endometrial Neoplasms 34 Neoplasms 31 Parkinson Disease 4, Autosomal Dominant Lewy Body 28 Neoplasm Metastasis 28 Head and Neck Neoplasms 24 Prostatic Neoplasms 20 Carcinoma 19 Esophageal Neoplasms 18 Urinary Bladder Neoplasms 16 Colorectal Neoplasms 16 Uterine Cervical Neoplasms 15 Oropharyngeal Neoplasms 14 Carcinoma, Transitional Cell 14 Carcinoma, Squamous Cell 14 Esophageal Squamous Cell Carcinoma 13 Brain Neoplasms 12 Stomach Neoplasms 10 Pancreatic Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 10 Mouth Neoplasms 9 Laryngeal Neoplasms 9 Carcinoma, Ovarian Epithelial 9

Interventions

enfortumab vedotin 2 zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × Carboplatin × 1 year × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡